Event Information

Time: 14:00-17:00, March 1, 2013

Venue: NanKang Software Park Phase I Conventional Center
(2F., Building A, No.19-10, Sanchong Rd., Taipei, Taiwan)

Organizer: TRPMA/ Biotechnology and Pharmaceutical Industries Promotion Office, MOEA/ Development Center for Biotechnology

Advisor: Industrial Development Bureau, MOEA

Agenda:

 Time

Content

 13:45~14:00

Registration

 14:00~14:30

Overview of Taiwan Bio-Industry
Dr. Chien-Hsin Daniel Cheng, Director of BPIPO

 14:30~15:00

Discovery of Novel SHP-1 Agonists from Sorafenib for the Treatment of HCC
Dr. Kuen-Feng Chen, NTUH

 15:00~15:30

TaiGen: A Research-based and Product-driven Biopharmaceutical Company/
Dr. Richard King, Senior Vice President of TaiGen Biotechnology

 15:30~15:40

Coffee Break

 15:40~16:10

Celgene-An Emerging Success Story
Mr. Mark Alles, Executive Vice President, Global Head of Hematology and Oncology of Celgene Corporation

 16:10~16:40

Preclinical Biopharmaceutical Development: DCB Capability and Experience Sharing
Dr. Wei-Kuang Chi, Vice President of DCB

 16:40~17:00

Q&A

Honorable guests took picture together.

Overview of Taiwan Bio-Industry/ Dr. Chien-Hsin Daniel Cheng, Director of BPIPO

Discovery of Novel SHP-1 Agonists from Sorafenib for the Treatment of HCC/ Dr. Kuen-Feng Chen, NTUH

TaiGen: A Research-based and Product-driven Biopharmaceutical Company/ Dr. Richard King, Senior Vice President of TaiGen Biotechnology

Celgene-An Emerging Success Story/ Mr. Mark Alles, Executive Vice President, Global Head of Hematology and Oncology of Celgene Corporation

Preclinical Biopharmaceutical Development: DCB Capability and Experience Sharing/ Dr. Wei-Kuang Chi, Vice President of DCB